ALKERMES | ALKS - Gewinn Vor Steuern

Aktienkurs
33.33
Täglich Wechseln
-0.03 -0.09%
Monatlich
19.04%
Jährlich
21.02%
Q2 Prognose
32.39




Gewinn Vor Steuern Veränderung Datum
AbbVie USD 4.38B 1.92B 2025-09
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Amgen USD 3.92B 2.35B 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Gilead Sciences USD 3.64B 1.21B 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
J&J USD 4.97B 2.53B 2025-12
Merck USD 6.74B 22M 2025-09
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Otsuka Holdings JPY 75.26B 91.16B 2025-12
Pfizer USD 3.33B 290M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09